Angiex

Cambridge, MA · Founded 2015 · Privately Held (backing)

Developer of vascular-targeted biotherapeutics designed for the treatment of solid cancers and other diseases of pathological angiogenesis. Angiex is based in Cambridge, MA and was founded in 2015. Its last reported valuation was $183 million in Aug 2021. It has raised $98.7 million across 2 recorded rounds; the latest was a $22 million early-stage round in Jul 2025.

Last reported valuation
$182.6M
Oct 2026
Priced at
—
Total raised
$98.7M
Last round
Early Stage VC
Jul 2025

Who backs Angiex?

19 investors
InvestorType
MassChallenge—
Mana VenturesVenture capital
GaingelsVenture capital
Keiretsu ForumOther
K5 GlobalVenture capital
Spacestation (UK)—
Thiel CapitalFamily office
Green Meadow VenturesFamily office
Apeiron Investment GroupFamily office
Starling Ventures—
+ 9 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Angiex investors

19 investors are on record for Angiex, including MassChallenge, Mana Ventures, Gaingels and Keiretsu Forum. By type, the record holds 3 venture capital firms and 3 family offices. The early-stage round in Jul 2025 drew 137 investors.

Free account
More of Angiex with a free account
  • ·The complete investor list: 19 names
  • ·Watch Angiex: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 19 firms already write checks for companies like Angiex. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View